- Home
- EPC vs OCUL Comparison
EPC vs OCUL Comparison
Compare EPC & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- OCUL
- Stock Information
- Founded
- EPC 1999
- OCUL 2006
- Country
- EPC United States
- OCUL United States
- Employees
- EPC N/A
- OCUL N/A
- Industry
- EPC Package Goods/Cosmetics
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- OCUL Health Care
- Exchange
- EPC Nasdaq
- OCUL Nasdaq
- Market Cap
- EPC 1.5B
- OCUL 1.2B
- IPO Year
- EPC 2000
- OCUL 2014
- Fundamental
- Price
- EPC $31.70
- OCUL $7.34
- Analyst Decision
- EPC Buy
- OCUL Strong Buy
- Analyst Count
- EPC 7
- OCUL 9
- Target Price
- EPC $36.57
- OCUL $16.22
- AVG Volume (30 Days)
- EPC 522.8K
- OCUL 1.7M
- Earning Date
- EPC 05-07-2025
- OCUL 05-06-2025
- Dividend Yield
- EPC 1.89%
- OCUL N/A
- EPS Growth
- EPC N/A
- OCUL N/A
- EPS
- EPC 1.86
- OCUL N/A
- Revenue
- EPC $2,243,200,000.00
- OCUL $63,723,000.00
- Revenue This Year
- EPC $0.68
- OCUL $13.59
- Revenue Next Year
- EPC $2.12
- OCUL $13.88
- P/E Ratio
- EPC $17.07
- OCUL N/A
- Revenue Growth
- EPC N/A
- OCUL 9.03
- 52 Week Low
- EPC $26.65
- OCUL $4.06
- 52 Week High
- EPC $41.50
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- EPC 59.14
- OCUL 48.32
- Support Level
- EPC $29.16
- OCUL $7.36
- Resistance Level
- EPC $29.92
- OCUL $8.04
- Average True Range (ATR)
- EPC 0.68
- OCUL 0.49
- MACD
- EPC 0.22
- OCUL -0.06
- Stochastic Oscillator
- EPC 99.22
- OCUL 50.27
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.